# A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

> **NCT03864601** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 14C-JNJ-56136379

## Key facts

- **NCT ID:** NCT03864601
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2019-06-14
- **Final completion:** 2019-06-14
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03864601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03864601, "A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03864601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*